Your browser doesn't support javascript.
loading
How long should we continue crizotinib in ALK translocation-positive inflammatory myofibroblastic tumors? Long-term complete response with crizotinib and review of the literature.
Alan, Ozkan; Kuzhan, Okan; Koca, Sinan; Telli, Tugba Akin; Basoglu, Tugba; Ercelep, Ozlem; Filinte, Deniz; Sengul, Yildiz; Arikan, Huseyin; Kaya, Serap; Babacan, Nalan Akgul; Dane, Faysal; Yumuk, Perran Fulden.
Affiliation
  • Alan O; Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Marmara University, Istanbul, Turkey.
  • Kuzhan O; Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Yeditep University, Istanbul, Turkey.
  • Koca S; Division of Medical Oncology, Umraniye Research and Training Hospital, Istanbul, Turkey.
  • Telli TA; Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Marmara University, Istanbul, Turkey.
  • Basoglu T; Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Marmara University, Istanbul, Turkey.
  • Ercelep O; Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Marmara University, Istanbul, Turkey.
  • Filinte D; Department of Pathology, Faculty of Medicine, Marmara University, Istanbul, Turkey.
  • Sengul Y; Department of Radiology, Faculty of Medicine, Marmara University, Istanbul, Turkey.
  • Arikan H; Department of Internal Medicine, Faculty of Medicine, Marmara University, Istanbul, Turkey.
  • Kaya S; Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Marmara University, Istanbul, Turkey.
  • Babacan NA; Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Marmara University, Istanbul, Turkey.
  • Dane F; Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Marmara University, Istanbul, Turkey.
  • Yumuk PF; Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Marmara University, Istanbul, Turkey.
J Oncol Pharm Pract ; 26(4): 1011-1018, 2020 Jun.
Article in En | MEDLINE | ID: mdl-31615346
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Translocation, Genetic / Crizotinib / Anaplastic Lymphoma Kinase / Neoplasms, Muscle Tissue / Antineoplastic Agents Limits: Adult / Child / Humans / Male Language: En Journal: J Oncol Pharm Pract Journal subject: FARMACIA Year: 2020 Type: Article Affiliation country: Turkey
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Translocation, Genetic / Crizotinib / Anaplastic Lymphoma Kinase / Neoplasms, Muscle Tissue / Antineoplastic Agents Limits: Adult / Child / Humans / Male Language: En Journal: J Oncol Pharm Pract Journal subject: FARMACIA Year: 2020 Type: Article Affiliation country: Turkey